Although still unable to cure patients infected with HIV, we have increasingly diversified means of preventing the disease, more than forty years after the first cases were identified in France.
The latest is PrEP (pre-exposure prophylaxis), sometimes referred to as the “anti-AIDS pill”.
Authorized for the first time in France in 2016, it is gradually finding its place with more than 42,000 users at the start of 2022. But despite its progress in certain particularly exposed groups, it is slow to influence the dynamics of new cases.
The treatment consists of taking PrEP, which combines two antiretrovirals (Truvada or generics), before a situation where there is a risk of being contaminated, to block the transmission of the virus.
The treatment can be taken on an ad hoc basis, or continuously if the way of life requires it (partners often changing, sex workers, etc.).
Male homosexuals, who are one of the most exposed groups (43% of new cases)…
This article is for subscribers only.
You have 80% left to discover.
Pushing back the limits of science is also freedom.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login
